UNSPSC 51263006: Terazosin

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H25N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8L5014XET7, chemically known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine but generally known as terazosin, which bears US NIH Compound Identifier 5401. European Medicines Agency schedules Terazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10907MIG.

UNSPSC 51263006 Terazosin, a Commodity code, nominally covers a specific pharmaceutical product, but the recent solicitation activity shows a significant mismatch between the code assignment and the work actually being procured. Seminole County, Florida posted an IFB in June 2026 seeking naloxone and safe drug deactivation systems—neither of which aligns with the terazosin product category. The code shows little relevant recent activity grounded in its actual pharmaceutical scope, and state and local buyers appear to be tagging broad health-supply and emergency-response procurements with codes that do not reflect the specific goods being acquired.

Without additional recent opportunities under this code that reflect genuine terazosin procurement or related pharmaceutical acquisitions, the demand signal for vendors pursuing terazosin sales to state and local bodies remains unclear. The single visible record—the Seminole County naloxone and drug deactivation systems IFB with a response deadline of July 26, 2023—does not support a business development strategy focused on this commodity code. Vendors active in state and local pharmaceutical supply should monitor how issuing bodies continue to tag these opportunities and may find more actionable demand under broader pharmaceutical supply or emergency-response family codes.